Thadhani et al. have found that treatment with paricalcitol (a VDR activator) in CKD patients reduces parathyroid hormone (PTH) levels within 4 weeks of commencing treatment versus a placebo [10], however, did not impact the primary outcome ( LV mass), but did reduce the number of CV disease-related hospitalizations over the trial period. This evidence concerns the gene VDR and chronic kidney disease.